ORIGINAL INVESTIGATION. Osteoporosis and Fractures in Postmenopausal Women Using Estrogen
|
|
- Toby Ellis
- 5 years ago
- Views:
Transcription
1 ORIGINAL INVESTIGATION Osteoporosis and Fractures in Postmenopausal Women Using Heidi D. Nelson, MD, MPH; Joanne Rizzo, MA; Emily Harris, PhD; Jane Cauley, DrPH; Kristine Ensrud, MD, MPH; Douglas C. Bauer, MD; Eric Orwoll, MD; for the Study of Osteoporotic Fractures Research Group Background: Previous studies demonstrate that postmenopausal women who use estrogen are somewhat protected from bone loss and fractures compared with nonusers, but the extent to which estrogen users remain at risk for osteoporosis and fractures is uncertain. Objective: To determine long-term probabilities for incident fractures among postmenopausal estrogen users. Methods: We examined data from the Study of Osteoporotic Fractures, a prospective cohort study with 10 years of follow-up ( ). This cohort includes 8816 women 65 years and older from community settings in 4 areas of the United States. Main Outcome Measures: Hip, wrist, vertebral, and nonvertebral fractures. Results: At baseline, using criteria developed by the World Health Organization, 40% of continuous estrogen users were osteopenic and 13% were osteoporotic at the hip or spine. Although women currently using estrogen lost less bone density than past users or those who never used estrogen, all user groups on average lost bone from the hip and calcaneus. During 10 years of observation, the adjusted probability of nonvertebral fractures was 19.6% for continuous estrogen users, similar to current partial users and lower than past users and those who never used estrogen (P.05). These comparisons were similar for hip, wrist, and vertebral fractures. Conclusions: Although estrogen use is associated with reduced prevalence of low bone density, less bone loss, and lower probabilities for fractures, osteoporosis and fractures are common in older women who used estrogen continuously since menopause. users should be considered in strategies designed to detect, prevent, and treat osteoporosis. Arch Intern Med. 2002;162: From the Departments of Medical Informatics and Outcomes Research (Dr Nelson) and Medicine (Drs Nelson and Orwoll), Oregon Health and Science University, Portland; the Medical Service, Veterans Affairs Medical Center, Portland (Dr Nelson); the Center for Health Research, Northwest Kaiser Permanente, Portland (Ms Rizzo and Dr Harris); the Department of Epidemiology, University of Pittsburgh, Pittsburgh, Pa (Dr Cauley); the Department of Internal Medicine and Epidemiology, University of Minnesota, Minneapolis (Dr Ensrud); and the Department of Epidemiology and Biostatistics, University of California, San Francisco (Dr Bauer). The investigators in the Study of Osteoporotic Fractures Research Group are listed in a box on page OSTEOPOROSIS IS an enormous public health problem that most often affects postmenopausal women. Half of all postmenopausal women will have an osteoporosis-related fracture during their lives, including 25% who will develop a vertebral deformity 1 and 15% who will have a hip fracture. 2 Fracture rates are higher in older women than in similarly aged men, and approximately 80% of the economic burden of osteoporosis has been attributed to its occurrence in women. 3 The sex difference in fracture incidence may have several explanations, but postmenopausal reduction in estrogen levels and resulting bone loss has long been considered a major factor. The evidence linking estrogen deficiency and accelerated bone loss is unequivocal, and bone loss in the early postmenopausal period undoubtedly contributes to the increase in fractures occurring later in life. Hormone replacement therapy, consisting of estrogen with or without progestin, has been a primary approach for osteoporosis prevention. Randomized controlled trials of estrogen consistently demonstrate improvement or stabilization of bone density. A meta-analysis combining results of several 2-year prevention trials of opposed and unopposed regimens indicates increases in bone density of 7% at the lumbar spine, 4% at the femoral neck, and 4.5% at the forearm. 4 Large observational studies report a 20% to 35% reduction in hip fractures associated with estrogen use, 5-7 as well as reductions in wrist, 8,9 vertebral, 8 and all nonvertebral fractures. 9 A recent metaanalysis of 22 trials of estrogen reported an overall 27% reduction in nonvertebral fractures (relative risk, 0.73 [95% confidence interval, ]). 10 Several trials included in the meta-analysis did not verify fractures radiographically, included traumatic fractures, or included women who were hospitalized or had secondary causes of osteoporosis limiting generalizability. Initial results of the Women s Health Initia- 2278
2 tive, a large randomized controlled prevention trial of combined estrogen use for 5 years, indicated reduced risk for all fractures (hazard ratio, 0.69 [adjusted 95% confidence interval, ]). 11 One arm of another trial conducted on nonosteoporotic women in early menopause indicated a protective effect for nonvertebral fractures (relative risk, 0.29 [95% confidence interval, ]). 12 Several trials, however, have not provided strong evidence of benefit These studies demonstrate that estrogen users are somewhat protected from bone loss and fractures compared with nonusers, but they do not, however, describe to what extent estrogen users remain at risk for osteoporosis and fractures. Although the protective effect of estrogen is important, women who choose to receive estrogen supplementation may still be at substantial risk, especially later in life when most fractures occur. We have previously shown that women who use estrogen have a lower risk of fractures and lose less bone than those who had never used estrogen (never users). 9,18 The purpose of the present study is to expand on previous work and determine long-term probabilities for fractures among postmenopausal estrogen users, particularly those who have used estrogen continuously since menopause. To address our research question, we examined data collected prospectively over 10 years in different estrogen user groups in the Study of Osteoporotic Fractures (SOF) cohort. METHODS SUBJECTS Ambulatory, community-dwelling women 65 years and older were recruited from 1986 to 1988 in Portland, Ore; Minneapolis, Minn; Baltimore, Md; and the Monongahela Valley, Pa, from population-based lists. 19 The study group consisted of 9704 white women; black women (because of their low incidence of hip fractures) and white women who had undergone bilateral hip replacement or had an earlier hip fracture were excluded. The appropriate committees on human research approved the study, and all the women provided written informed consent. INTERVIEWS AND EXAMINATIONS We obtained data for this study from questionnaires and examinations performed at multiple SOF visits from 1986 to 1998 (Figure 1). Methods for collecting baseline descriptive variables have been previously described. 20 Type of menopause (surgical or natural), alcohol use in the previous year, and current and past cigarette smoking were obtained by a questionnaire reviewed with the participant by a trained interviewer. Total calcium intake was assessed by a food frequency questionnaire and by interview using standardized food models to estimate portions 21 and included supplemental sources. A modified Paffenbarger questionnaire was used to assess sports and recreation activity for the previous year. 22 History of osteoporosis was ascertained by asking women if a physician had ever told them whether they had osteoporosis or a spine fracture. History of fracture after age 50 years and prior to entry to the study was based on self-report. Women were asked whether they were currently using sedatives, anxiolytics, and corticosteroids and if they had ever used thyroid supplements. Cognitive function was assessed using the Modified Mini-Mental State Examination. 23 Age was determined at baseline, and weight was obtained at each visit by balance beam scale. Baseline Visit 2 Visit 3 Visit 4 Visit 5 Visit 6 Use and Current Subject Characteristics Calcaneal BMD Vertebral X-ray Begin Observation for Incident Fractures Spine BMD Mean, 3.7 y Total Hip BMD Mean, 5.8 y Vertebral X-ray Mean, 3.6 y Calcaneal BMD Total Hip BMD Mean, 9.8 y Figure 1. Measurement of variables; data were collected serially over a mean 9.8 years of follow-up. BMD indicates bone mineral density. Participants were categorized according to their oral estrogen use based on their responses to intervieweradministered questionnaires obtained at each SOF visit. Participants were asked to bring all medications to the clinic for verification of use, preparation, and dosage at visits 1 and 4. Also, pictures of tablets were presented to participants to assist them in the recollection of previously prescribed hormone preparations. Duration of use was based on their recall of previous use. Use of progestins was not specifically considered in this study because previous analyses showed no difference in fracture rates among unopposed compared with combination users, and there were few combination users in SOF. 9 Only a very small number of participants used nonoral forms of estrogen, and they were not included. Current users were those who reported using estrogen at the time of an interview. Those who used estrogen without interruption from the onset of their surgical or natural menopause until their SOF visit were considered continuous estrogen users. Age at menopause was defined as age of last menstrual period or age at hysterectomy with bilateral oophorectomy. Women who reported that they had a hysterectomy without bilateral oophorectomy, those who were unsure of their last period or oophorectomy status, or those with missing values were assigned a menopause age equal to the mean of the other women in the study (49 years) and included in the analysis. users who had taken estrogen for at least 1 year but not continuously since menopause were considered partial users, and those who had never used estrogen for at least 1 year were considered never users. Partial users were further categorized based on current or past use (ie, partial users who were using estrogen at the time of the assessment were considered current partial users). use status was assessed repeatedly at intervals of 2 to 3 years at follow-up visits. Bone mineral density (calculated as grams per centimeters squared) of the total hip was measured using dual energy x-ray absorptiometry (QDR 1000; Hologic, Waltham, Mass) at the second and fourth SOF visits. Mean time between measurements was 3.6 years. We measured calcaneal bone mineral density using single-photon absorptiometry (OsteoAnalyzers; Siemens-Osteon, Wahiawa, Hawaii) at the first visit, and single x-ray absorptiometry at the fourth visit for a mean follow-up time of 5.8 years. Spine bone mineral density was measured once by dual x-ray absorptiometry at the second SOF visit. Details of these measurement methods have been previously published. 18,
3 Table 1. Baseline Characteristics of Subjects Characteristic (n = 373) User Groups (n = 926) (n = 1540) (n = 5977) Mean years taking estrogen Previous diagnosis of osteoporosis, % 13 29* Fracture after age 50 y, % 30* 40 36* 40 Age, mean, y 69.3* 70.7* 70.9* 72.1 Weight, mean, kg 66.1* 64.7* 66.4* 67.6 Surgical menopause, % 38* 22* 18* 8 Alcohol use in the past year, % 75* 77* 76* 67 Smoker, % Current * 33* 34* 28 Physical activity, mean, kcal/wk 2010* 1898* 1858* 1481 Calcium intake, mean, mg/d 1178* 1424* 1201* 1036 Modified Mini-Mental State Examination, % with score 23 14* 14* 14* 20 Current use of sedatives/anxiolytics, % 41* 37* 35* 29 Current use of steroids, % 4* 3* 2 2 Ever used thyroid supplements, % 31* 24* 25* 17 Initial bone density measurements Total hip bone density, mean, mg/cm * 0.788* 0.766* % Osteopenic at total hip 38* 48* % Osteoporotic at total hip 4* 11* 11* 15 Spine bone density, mean, mg/cm * 0.904* 0.859* % Osteopenic at spine 29* % Osteoporotic at spine 12* 26* Total hip or spine % Osteopenic at total hip or spine 40* 47* % Osteoporotic at total hip or spine 13* 29* *Comparisons significant at P.05; frequencies compared by 2, means by least-square estimates, with never users as reference group. Bone density means and frequencies are age and weight adjusted. Bone density measurements were obtained at visit 2. Defined by World Health Organization criteria: bone density 2.5 or more SDs below the young healthy population mean defines osteoporosis; between 1 and 2.5 SDs below the mean defines osteopenia. ASCERTAINMENT OF FRACTURES Study participants were contacted by postcard or telephone every 4 months to inquire about incident fractures. All incident, nontraumatic, nonvertebral fractures were recorded and radiographically confirmed as they occurred for the entire SOF cohort over a mean 9.8 years of observation until June Details about methods of identifying new fractures during follow-up in SOF have been previously published. 25 Incident vertebral fractures were determined by radiographic morphometric criteria 26 over a period of 3.7 years. STATISTICAL ANALYSIS Frequencies and means were determined for baseline characteristics of each estrogen user group and compared by 2 and least-square means tests using never users as the reference group. Frequencies of women identified as osteopenic and osteoporotic were determined using criteria developed by a consensus group of the World Health Organization (WHO) (bone density 2.5 SDs or more below the young healthy population mean defines osteoporosis; bone density between 1 and 2.5 SDs below the mean defines osteopenia). 27 Multiple linear regression was used to compare rates of bone loss. Two multivariable models were developed to test differences between groups. One model included age and weight only, and another fully adjusted model included 14 variables known to influence bone density and fracture outcomes (age, weight, physical activity, body mass index, calcium use, hysterectomy status, general health status, thiazide use, mental state examination, alcohol use, smoking status, history of falls, sedative use, and thyroid supplement use). 9,20,28 For each comparison, results were similar for both models, and we included only the age- and weight-adjusted models in this report to graph probability of fracture over time. All analyses were conducted twice, once including women with a self-reported diagnosis of osteoporosis prior to entry to SOF and once excluding them. We used stratified Cox proportional hazard regression adjusted for age and weight to determine the probabilities of fracture in each of the estrogen user groups. Because estrogen use varied over time from baseline, we censored follow-up time in the analysis when estrogen use status changed. Otherwise, follow-up time was measured from baseline through first fracture or last contact. To adjust for differences between age and weight in the 4 groups, we equalized the means of these variables and then fit a Cox proportional hazard model stratified by estrogen use group. We used SAS software for all analyses (SAS Institute Inc, Cary, NC). RESULTS A total of 8816 women who underwent baseline examinations in the SOF had estrogen use variables for this analysis. Of these women, 373 used estrogen continuously from the onset of surgical or natural menopause until their baseline visit for a mean duration of 24.4 years (Table 1). A total of 2466 women used estrogen partially between the time of menopause until baseline, and 2280
4 % Loss per Year Total Hip Calcaneus 1.66 User Groups 926 of them were using estrogen at the time of the baseline visit. A total of 5977 women never used estrogen for at least 1 year. Twice the proportion of current partial estrogen users (29%) reported that a physician had previously diagnosed them as having osteoporosis prior to enrollment in SOF compared with the other user groups. Approximately one third of all subjects reported at baseline that they had previously had a fracture after age 50 years, including 30% of the group using estrogen continuously since menopause. user groups differ by several baseline characteristics. and partial users are younger and weigh less than never users (P.05). A higher proportion of continuous (38%) and partial users (22% current and 18% past users) have a history of surgical menopause compared with never users (8%; P.05). Groups also vary by their alcohol use, smoking status, levels of physical activity, calcium intake, mental state examination, and use of sedatives and/or anxiolytics, corticosteroids, and thyroid medications as indicated in Table 1. BONE DENSITY Figure 2. Mean bone density loss by estrogen user group. Women in all estrogen user groups lost bone density at both the total hip and calcaneus. Asterisks indicate values significantly different from those of never users from multiple linear regression models adjusted for age and weight (P.05). Although fewer estrogen users have low bone density at baseline compared with never users, a substantial percentage of women in all estrogen user groups are osteopenic or osteoporotic by WHO criteria (Table 1, lower section). Among continuous users, the prevalence of total hip osteopenia is 38% and osteoporosis, 4%, and the prevalence of spine osteopenia is 29% and osteoporosis, 12%. The rates of osteoporosis for current partial users are generally intermediate between continuous and never users for the hip and spine. Rates for past users are closer to those of never users. All groups, on average, lost bone density over time at the total hip and calcaneus (Figure 2). users had average rates of bone loss of 0.31% per year at the total hip and 0.99% per year at the calcaneus, which were similar to those of current partial users. Rates for continuous and current partial users were substantially lower than those of nonusers for both the hip and calcaneus (P.05). users lost significantly more bone density at these sites than never users (P.001). Rates Probability Table 2. Probabilities of Incident Fractures at 5 and 10 Years* Site (n = 327) User Groups Current Partial (n = 874) (n = 1921) Years of Follow-up Figure 3. Probability of nonvertebral fractures. Probabilities are adjusted for age and weight. of bone loss at both sites for all groups, as well as comparisons between groups, are similar when excluding women with a previous diagnosis of osteoporosis and when using the fully adjusted model. INCIDENT FRACTURES (n = 6300) All nonvertebral 5 y y Hip 5 y y Wrist 5 y y *Data are percentage of patients. Comparisons significant at P.05 by Cox proportional hazard models adjusting for age and weight with never users as reference group. The probability of any nonvertebral fracture for continuous estrogen users over 10 years of observation is 19.6% after adjustment for age and weight using Cox proportional hazard models (Table 2). This rate is similar for current partial users (22.4%), but lower than past (29.6%) and never (30.9%) users (P.001) (Figure 3). The rate for past users is not significantly lower than never users at 10 years. and current partial users continue to be at risk for hip (10-year rates: 2.8% for continuous and 2.8% for current partial users) and wrist fractures (10- year rates: 3.3% for continuous and 3.5% for current partial users), albeit at lower rates than never users (P.01) (Figure 4 and Figure 5). Wrist and hip fracture probabilities for past users are similar to never users. When the same analysis is performed excluding women who reported at baseline that they previously had been told that they had osteoporosis, the probabilities for 2281
5 Probability Years of Follow-up Figure 4. Probability of hip fractures. Probabilities are adjusted for age and weight. Probability Years of Follow-up Figure 5. Probability of wrist fractures. Probabilities are adjusted for age and weight. fracture decrease slightly for all groups at all sites. Differences between groups remain the same. The probability of an incident vertebral fracture (over 3.7 years of observation) was 2.5% among continuous users and 4.0% among never users. Differences between past and never users remained the same. To determine if the continuous users who fractured are different from those who did not, we compared their baseline characteristics. users who sustained fractures are slightly older (70.2 vs 69.2 years; P=.03), are more likely to have smoked cigarettes (55.3% vs 41.5%; P=.04) and more likely to take sedative or anxiolytic medications (48.7% vs 35.9%; P=.05) than those who did not fracture. They did not differ on any of the other baseline characteristics. COMMENT Our analysis of estrogen users in the SOF cohort found that among older women using estrogen since menopause, a substantial proportion met diagnostic criteria for osteopenia or osteoporosis; most lost bone density; and they had 10-year fracture rates of 19.6% for nonvertebral, 2.8% for hip, and 3.3% for wrist fractures. These outcomes for continuous estrogen users have not been previously reported. How the determinants of osteoporosis in estrogen users, or its prevention and treatment, differ from similar processes in women not using estrogen is not known. In our study, 80% of women experienced bone loss while receiving estrogen therapy. The group experiencing the least bone loss (current partial users) included women who had started estrogen more recently than the continuous users. Other studies indicate that the protective effect of estrogen persists for 10 years or more for women in the early postmenopausal period 29 and for at least 2 to 3 years in older women A separate evaluation of hip scans from SOF indicated that estrogen not only influences bone density but also seems to increase mechanical strength of the proximal femur by improving its geometric properties. 35 The nature of bone loss in older women using estrogen deserves additional study. Our results are consistent with our previous findings that women who use estrogen have a lower risk of fractures than never or past users, particularly if initiated early after menopause. 9,36 However, about 1 in 5 women experienced a fracture in 10 years, indicating that a substantial health burden of osteoporosis persists among women using estrogen. When considering the selfselection and lifestyle biases that probably lead to an overestimation of the beneficial effects of estrogen in observational studies, the unbiased effects of estrogen may be even more modest. The bone loss and frequency of osteopenia, osteoporosis, and fractures we observed in estrogen users indicate that, to some extent, skeletal fragility develops in women using estrogen. However, other causes of fractures that are not estrogen dependent, such as falls, become more frequent with age and may become more important than the estrogen effect. The information available in our study does not permit a comparison of these effects. theless, our conclusion that fractures are common in estrogen users emphasizes the need for additional study of the mechanisms of fracture. Some clinical guidelines imply that estrogen users do not require any assessments of skeletal health, 42 and clinicians and patients may feel that estrogen users are adequately protected from fractures. The findings of this study indicate that estrogen users remain at risk, and perhaps they should be considered in screening and treatment guidelines. The National Osteoporosis Foundation recommendations include the need for ongoing bone density assessments in estrogen users. 43 Although the usefulness of this approach has not been tested, identifying low bone density in estrogen users could prove beneficial. For instance, other preventive measures could be instituted such as improving calcium and vitamin D nutrition, exercise, and modifying other risk factors. Other therapies, such as bisphosphonates, may also be indicated. Use of estrogen combined with other therapies is being explored. Controlled trials of the effectiveness of all these strategies in reducing fractures are needed. This study has several limitations. Randomized controlled trials of older women with bone density and fracture end points would provide a more accurate estimate of the risk of osteoporosis in estrogen users. Despite our attempts to control for likely confounders, bias introduced by other unmeasured variables could be important 2282
6 Investigators in the Study of Osteoporotic Fractures Research Group University of California, San Francisco (Coordinating Center): S. R. Cummings (principal investigator), M. C. Nevitt (coinvestigator), D. C. Bauer (coinvestigator), K. Stone (project director), D. M. Black (study statistician), H. K. Genant (director, central radiology laboratory), P. Mannen (research associate), T. Blackwell, W. S. Browner, M. Cockrell, T. Duong, C. Fox, S. Harvey, M. Jaime-Chavez, L. Y. Lui, G. Milani, L. Nusgarten, L. Palermo, E. Williams, D. Tanaka, and C. Yeung. University of Maryland, Baltimore: M. Hochberg (principal investigator), J. C. Lewis (project director), D. Wright (clinic coordinator), R. Nichols, C. Boehm, L. Finazzo, B. Hohman, T. Page, S. Trusty, H. Kelm, T. Lewis, and B. Whitkop. University of Minnesota, Minneapolis: K. Ensrud (principal investigator), K. Margolis (coinvestigator), P. Schreiner (coinvestigator), K. Worzala (coinvestigator), M. Oberdorfer (project director), E. Mitson (clinic coordinator), C. Bird, D. Blanks, F. Imerker-Witte, K. Jacobson, K. Knaught, N. Nelson, E. Penland-Miller, and G. Saecker. University of Pittsburgh, Pittsburgh, Pa: J. A. Cauley (principal investigator), L. H. Kuller (coprincipal investigator), M. Vogt (coinvestigator), L. Harper (project director), L. Buck (clinic coordinator), C. Bashada, D. Cusick, G. Engleka, A. Flaugh, A. Githens, M. Gorecki, D. Medve, M. Nasim, C. Newman, S. Rudovsky, N. Watson, and D. Lee. The Kaiser Permanente Center for Health Research, Portland, Ore: T. Hillier (principal investigator), E. Harris (coprincipal investigator), E. Orwoll (coinvestigator), H. Nelson (coinvestigator), Mikel Aiken (biostatistician), Marge Erwin (project administrator), Mary Rix (clinic coordinator), Jane Wallace, Kathy Snider, Kathy Canova, Kathy Pedula, and Joanne Rizzo. in observational studies because estrogen users differ from nonusers in many ways. The advantage of this study, however, is that reliable prospective bone density and fracture outcomes have been collected on women with a wide range of estrogen use history, including a group of women with a mean of 24.4 years of continuous estrogen use. The cohort can be considered representative of similar community-dwelling women. Randomized controlled trials of estrogen replacement in postmenopausal women, even large trials, will not address the issue adequately unless they are of very long duration. Another limitation of the present analysis is that estrogen use was determined by patient report and is subject to inaccuracy. We were not able to determine adherence, and our measures are not reliable enough to stratify effects by dosage or duration of use. We attempted to minimize this bias by strictly defining our continuous estrogen group as those who had been receiving estrogen since surgical or natural menopause. This approach should be less prone to error than using exact years of use as the basis of categorization. Because subjects were repeatedly questioned about continuing use every 2 to 3 years during the study, use estimates should be reliable. We did not investigate users of nonoral estrogen because previous analyses found that there were few in SOF, 44 and their inclusion did not influence our results. Our estimates of the effects of partial estrogen use must be considered preliminary. Although the rates of bone loss and probabilities of fracture in these groups are substantial, the relative effects of current compared with past use must be defined more carefully in specifically designed studies. In summary, we found that prolonged postmenopausal estrogen use provided incomplete protection against bone loss and osteoporotic fractures. Osteoporosis and fractures were common in women who had used estrogen since menopause, and clinicians cannot assume that women using estrogen are fully protected from fractures. Efforts should be directed at identifying those at continued risk while using estrogen and at developing and testing the effectiveness of new management options for women who have osteoporosis and are at high risk of fractures despite long-term use of estrogen. Accepted for publication April 24, This study was funded by grants AG05407, AR35582, AG05394, AR35584, and AR35583 from the US Public Health Service, Rockville, Md. Corresponding author and reprints: Heidi D. Nelson, MD, MPH, Oregon Health and Science University, Mailcode BICC-504, 3181 SW Sam Jackson Park Rd, Portland, OR ( nelsonh@ohsu.edu). REFERENCES 1. Melton LJ III, Kan SH, Frye MA, Wahner HW, O Fallon WM, Riggs BL. Epidemiology of vertebral fractures in women. Am J Epidemiol. 1989;129: Barrett JA, Baron JA, Karagas MR, Beach ML. Fracture risk in the US Medicare population. J Clin Epidemiol. 1999;52: Ray NF, Chan JK, Thamer M, et al. Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: report from the National Osteoporosis Foundation. J Bone Miner Res. 1997;12: Wells G, Tugwell P, Shea B, et al, for the Osteoporosis Methodology Group and the Osteoporosis Research Advisory Group. Meta-analysis of the efficacy of hormone replacement therapy in treating and preventing osteoporosis in postmenopausal women. Endocr Rev. 2002;23: Kiel DP, Felson DT, Anderson JJ, Wilson PW, Moskowitz MA. Hip fracture and the use of estrogens in postmenopausal women: the Framingham Study. N Engl J Med. 1987;317: Naessen T, Persson I, Adami HO, Bergstrom R, Bergkvist L. Hormone replacement therapy and the risk for first hip fracture: a prospective, population-based cohort study. Ann Intern Med. 1990;113: Grodstein F, Stampfer MJ, Falkeborn M, Naessen T, Persson I. Postmenopausal hormone therapy and risk of cardiovascular disease and hip fracture in a cohort of Swedish women. Epidemiology. 1999;10: Maxim P, Ettinger B, Spitalny GM. Fracture protection provided by long-term estrogen treatment. Osteoporosis Int. 1995;5: Cauley JA, Seeley DG, Ensrud K, Ettinger B, Black D, Cummings SR. replacement therapy and fractures in older women. Ann Intern Med. 1995;122: Torgerson D, Bell-Syer S. Hormone replacement therapy and prevention of nonvertebral fractures: a meta-analysis of randomized trials. JAMA. 2001;285: Writing Group for the Women s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA. 2002; 288: Komulainen MH, Kroger H, Tuppurainen MT, et al. HRT and vit D in prevention of non-vertebral fractures in postmenopausal women: a 5 year randomized trial. Maturitas. 1998;31: Lufkin EG, Wahner HW, O Fallon WM, et al. Treatment of postmenopausal osteoporosis with transdermal estrogen. Ann Intern Med. 1992;117: Wimalawansa SJ. A four-year randomized controlled trial of hormone replacement and bisphosphonate, alone or in combination, in women with postmenopausal osteoporosis. Am J Med. 1998;104:
7 15. Hulley S, Grady D, Bush T, et al, for the Heart and /progestin Replacement Study (HERS) Research Group. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA. 1998;280: Cauley JA, Black D, Barrett-Connor E, et al. Effects of hormone replacement therapy on clinical fractures and height loss: the Heart and /progestin Replacement Study (HERS). Am J Med. 2001;110: Hulley S, Furberg C, Barrett-Connor E, et al. Noncardiovascular disease outcomes during 8.6 years of hormone therapy. JAMA. 2002;288: Ensrud KE, Palermo L, Black DM, et al. Hip and calcaneal bone loss increase with advancing age: longitudinal results from the Study of Osteoporotic Fractures. J Bone Miner Res. 1995;10: Cummings SR, Black DM, Nevitt MC, et al, for the Study of Osteoporotic Fractures Research Group. Appendicular bone density and age predict hip fracture in women. JAMA. 1990;263: Cummings SR, Nevitt MC, Browner WS, et al. Risk factors for hip fracture in white women. N Engl J Med. 1995;332: Cummings SR, Block G, McHenry K, Baron RB. Evaluation of two food frequency methods of measuring dietary calcium intake. Am J Epidemiol. 1987; 126: Paffenbarger RS Jr, Wing AL, Hyde RT. Physical activity as an index of heart attack risk in college alumni. Am J Epidemiol. 1978;108: Teng EL, Chui HC. The Modified Mini-Mental State (3MS) Examination. J Clin Psychiatry. 1987;48: Steiger P, Cummings SR, Black DM, Spencer NE, Genant HK. Age-related decrements in bone mineral density in women over 65. J Bone Miner Res. 1992;7: Nevitt MC, Cummings SR, Browner WS, et al. The accuracy of self-report of fractures in elderly women: evidence from a prospective study. Am J Epidemiol. 1992; 135: Nevitt MC, Ettinger B, Black DM, et al. The association of radiographically detected vertebral fractures with back pain and function: a prospective study. Ann Intern Med. 1998;128: Kanis JA. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. Osteoporos Int. 1994;4: Bauer DC, Browner WS, Cauley JA, et al. Factors associated with appendicular bone mass in older women. Ann Intern Med. 1993;118: Eiken P, Kolthoff N, Nielsen SP. Effect of 10 years hormone replacement therapy on bone mineral content in postmenopausal women. Bone. 1996;19:191S- 193S. 30. Christiansen C, Christiansen M, Transbol I. Bone mass in postmenopausal women after withdrawal of oestrogen/gestagen replacement therapy. Lancet. 1981;1: Ettinger B, Genant HK, Cann CE. Long-term estrogen replacement therapy prevents bone loss and fractures. Ann Intern Med. 1985;102: Grady D, Rubin SM, Petitti DB, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med. 1992;117: Lindsay R, Tohme JF. treatment of patients with established postmenopausal osteoporosis. Obstet Gynecol. 1990;76: Prince RL, Smith M, Dick IM, et al. Prevention of postmenopausal osteoporosis: a comparative study of exercise, calcium supplementation, and hormone replacement therapy. N Engl J Med. 1991;325: Beck TJ, Stone KL, Oreskovic TL, et al. Effects of current and discontinued estrogen replacement therapy on hip structural geometry: the Study of Osteoporotic Fractures. J Bone Miner Res. 2001;16: Cauley JA, Zmuda JM, Ensrud KE, Bauer DC, Ettinger B. Timing of estrogen replacement therapy for optimal osteoporosis prevention. J Clin Endocrinol Metab. 2001;86: Barrett-Connor E. Postmenopausal estrogen and prevention bias. Ann Intern Med. 1991;115: Cauley JA, Seeley DG, Browner WS, et al. replacement therapy and mortality among older women: the Study of Osteoporotic Fractures. Arch Intern Med. 1997;157: Keating N, Cleary P, Rossi A, Zaslavsky A, Ayanian J. Use of hormone replacement therapy by postmenopausal women in the United States. Ann Intern Med. 1999;130: Matthews KA, Kuller LH, Wing RR, Meilahn EN, Plantinga P. Prior use of estrogen replacement therapy, are users healthier than nonusers? Am J Epidemiol. 1996;143: Folsom AR, Mink PJ, Sellers TA, Hong CP, Zheng W, Potter JD. Hormonal replacement therapy and morbidity and mortality in a prospective study of postmenopausal women. Am J Public Health. 1995;85: American Association of Clinical Endocrinologists. AACE clinical practice guidelines for the prevention and treatment of postmenopausal osteoporosis. JFla Med Assoc. 1996;83: National Osteoporosis Foundation. Osteoporosis: Review of the Evidence for Prevention, Diagnosis, and Treatment and Cost-effectiveness Analysis. Washington, DC: National Osteoporosis Foundation; Cauley JA, Cummings SR, Black DM, Mascioli SR, Seeley DG. Prevalence and determinants of estrogen replacement therapy in elderly women. Am J Obstet Gynecol. 1990;163:
VERTEBRAL FRACTURES ARE THE
ORIGINAL CONTRIBUTION Long-term Risk of Incident Vertebral Fractures Jane A. Cauley, DrPH Marc C. Hochberg, MD, MPH Li-Yung Lui, MA, MS Lisa Palermo, MS Kristine E. Ensrud, MD, MPH Teresa A. Hillier, MD,
More informationALTHOUGH VITAMIN B-12 is known to influence the
0021-972X/04/$15.00/0 The Journal of Clinical Endocrinology & Metabolism 89(3):1217 1221 Printed in U.S.A. Copyright 2004 by The Endocrine Society doi: 10.1210/jc.2003-030074 Low Serum Vitamin B-12 Levels
More informationIN WOMEN, serum estradiol is an important determinant
0021-972X/98/$03.00/0 Vol. 83, No. 7 Journal of Clinical Endocrinology and Metabolism Printed in U.S.A. Copyright 1998 by The Endocrine Society Associations between Low Levels of Serum Estradiol, Bone
More informationBone mineral density testing: Is a T score enough to determine the screening interval?
Interpreting Key Trials CME CREDIT EDUCATIONAL OBJECTIVE: Readers will measure bone mineral density at reasonable intervals in their older postmenopausal patients Krupa B. Doshi, MD, CCD Department of
More informationAsmall number of studies have examined
Appendix B: Evidence on Hormone Replacement Therapy and Fractures B Asmall number of studies have examined directly the relationship between use of hormonal replacement therapy and risk of hip fracture
More informationBone Mineral Density and Risk of Breast Cancer
American Journal of Epidemiology Copyright 1998 by The Johns Hopkins University School of Hygiene and Public Health All rights reserved Vol. 148, No. 1 Printed in U.S.A. Bone Mineral Density and Risk of
More informationBody Mass Index as Predictor of Bone Mineral Density in Postmenopausal Women in India
International Journal of Public Health Science (IJPHS) Vol.3, No.4, December 2014, pp. 276 ~ 280 ISSN: 2252-8806 276 Body Mass Index as Predictor of Bone Mineral Density in Postmenopausal Women in India
More informationEfficacy of risedronate in men with primary and secondary osteoporosis: results of a 1-year study
Rheumatol Int (2006) 26: 427 431 DOI 10.1007/s00296-005-0004-4 ORIGINAL ARTICLE J. D. Ringe Æ H. Faber Æ P. Farahmand Æ A. Dorst Efficacy of risedronate in men with primary and secondary osteoporosis:
More informationMenopausal hormone therapy currently has no evidence-based role for
IN PERSPECTIVE HT and CVD Prevention: From Myth to Reality Nanette K. Wenger, M.D. What the studies show, in a nutshell The impact on coronary prevention Alternative solutions Professor of Medicine (Cardiology),
More informationORIGINAL ARTICLE. E. Barrett-Connor & S. G. Sajjan & E. S. Siris & P. D. Miller & Y.-T. Chen & L. E. Markson
Osteoporos Int (2008) 19:607 613 DOI 10.1007/s00198-007-0508-8 ORIGINAL ARTICLE Wrist fracture as a predictor of future fractures in younger versus older postmenopausal women: results from the National
More informationOSTEOPOROSIS: PREVENTION AND MANAGEMENT
OSTEOPOROSIS: OVERVIEW OSTEOPOROSIS: PREVENTION AND MANAGEMENT Judith Walsh, MD, MPH Departments of Medicine and Epidemiology and Biostatistics UCSF Definitions Key Risk factors Screening and Monitoring
More informationPrevalence of vertebral fractures on chest radiographs of elderly African American and Caucasian women
Osteoporos Int (2011) 22:2365 2371 DOI 10.1007/s00198-010-1452-6 ORIGINAL ARTICLE Prevalence of vertebral fractures on chest radiographs of elderly African American and Caucasian women D. Lansdown & B.
More informationAccuracy of Self-Reported Diagnosis of Hip Replacement
Arthritis Care & Research Vol. 62, No. 5, May 2010, pp 719 724 DOI 10.1002/acr.20111 2010, American College of Rheumatology ORIGINAL ARTICLE Accuracy of Self-Reported Diagnosis of Hip Replacement NEETA
More informationNIH Public Access Author Manuscript Endocr Pract. Author manuscript; available in PMC 2014 May 11.
NIH Public Access Author Manuscript Published in final edited form as: Endocr Pract. 2013 ; 19(5): 780 784. doi:10.4158/ep12416.or. FRAX Prediction Without BMD for Assessment of Osteoporotic Fracture Risk
More informationOriginal Article. Ramesh Keerthi Gadam, MD 1 ; Karen Schlauch, PhD 2 ; Kenneth E. Izuora, MD, MBA 1 ABSTRACT
Original Article Ramesh Keerthi Gadam, MD 1 ; Karen Schlauch, PhD 2 ; Kenneth E. Izuora, MD, MBA 1 ABSTRACT Objective: To compare Fracture Risk Assessment Tool (FRAX) calculations with and without bone
More informationVol. 332 No. 12 RISK FACTORS FOR HIP FRACTURE IN WHITE WOMEN 767
Vol. 332 No. 12 RISK FACTORS FOR HIP FRACTURE IN WHITE WOMEN 767 RISK FACTORS FOR HIP FRACTURE IN WHITE WOMEN STEVEN R. CUMMINGS, M.D., MICHAEL C. NEVITT, PH.D., WARREN S. BROWNER, M.D., M.P.H., KATIE
More informationDr Tuan V NGUYEN. Mapping Translational Research into Individualised Prognosis of Fracture Risk
Dr Tuan V NGUYEN Bone and Mineral Research Program, Garvan Institute of Medical Research, Sydney NSW Mapping Translational Research into Individualised Prognosis of Fracture Risk From the age of 60, one
More informationDiabetes and Incidence of Functional Disability in Older Women
Epidemiology/Health Services/Psychosocial Research O R I G I N A L A R T I C L E Diabetes and Incidence of Functional Disability in Older Women EDWARD W. GREGG, PHD 1 CAROL M. MANGIONE, MD, MPH 2,3 JANE
More informationOsteoporosis International. Original Article. Bone Mineral Density and Vertebral Fractures in Men
Osteoporos Int (1999) 10:265 270 ß 1999 International Osteoporosis Foundation and National Osteoporosis Foundation Osteoporosis International Original Article Bone Mineral Density and Vertebral Fractures
More informationMENOPAUSE IN women produces estrogen deficiency. Does Hormone-Replacement Therapy Prevent Fractures in Early Postmenopausal Women?
JOURNAL OF BONE AND MINERAL RESEARCH Volume 17, Number 3, 2002 2002 American Society for Bone and Mineral Research Does Hormone-Replacement Therapy Prevent Fractures in Early Postmenopausal Women? KAISA
More informationModule 5 - Speaking of Bones Osteoporosis For Health Professionals: Fracture Risk Assessment. William D. Leslie, MD MSc FRCPC
Module 5 - Speaking of Bones Osteoporosis For Health Professionals: Fracture Risk Assessment William D. Leslie, MD MSc FRCPC Case #1 Age 53: 3 years post-menopause Has always enjoyed excellent health with
More informationCan we improve the compliance to prevention treatment after a wrist fracture? Roy Kessous
Can we improve the compliance to prevention treatment after a wrist fracture? Roy Kessous Distal radius fracture in women after menopause is in many cases a first clinical indication for the presence of
More informationChallenging the Current Osteoporosis Guidelines. Carolyn J. Crandall, MD, MS Professor of Medicine David Geffen School of Medicine at UCLA
Challenging the Current Osteoporosis Guidelines Carolyn J. Crandall, MD, MS Professor of Medicine David Geffen School of Medicine at UCLA Whom to screen Which test How to diagnose Whom to treat Benefits
More informationCalcium Intake and Fracture Risk: Results from the Study of Osteoporotic Fractures
American Journal of Epidemiology Copyright 1997 by The Johns Hopkins University School of Hygiene and Public Health All rights reserved Vol. 145, No. 10 Printed in U.S.A. Calcium Intake and Fracture Risk:
More informationHormones and Healthy Bones Joint Project of National Osteoporosis Foundation and Association of Reproductive Health Professionals
Hormones and Healthy Bones Joint Project of National Osteoporosis Foundation and Association of Reproductive Health Professionals Literature Review (January 2009) Hormone Therapy for Women Women's Health
More informationHow can we tell who will fracture? Beyond bone mineral density to the new world of fracture risk assessment
Copyright 2008 by How can we tell who will fracture? Beyond bone mineral density to the new world of fracture risk assessment Dr. Bone density testing: falling short of expectations More than 25 years
More informationEffect of Alendronate on Risk of Fracture in Women With Low Bone Density but Without Vertebral Fractures
Original Contributions Effect of Alendronate on Risk of Fracture in Women With Low Bone Density but Without Vertebral Fractures Results From the Fracture Intervention Trial Steven R. Cummings, MD; Dennis
More informationCurrent Issues in Osteoporosis
Current Issues in Osteoporosis California AACE 18TH Annual Meeting & Symposium Marina del Rey, CA September 15, 2018 Michael R. McClung, MD, FACP,FACE Director, Oregon Osteoporosis Center Portland, Oregon,
More informationASJ. How Many High Risk Korean Patients with Osteopenia Could Overlook Treatment Eligibility? Asian Spine Journal. Introduction
Asian Spine Journal Asian Spine Clinical Journal Study Asian Spine J 2014;8(6):729-734 High http://dx.doi.org/10.4184/asj.2014.8.6.729 risk patients with osteopenia How Many High Risk Korean Patients with
More informationSkeletal Manifestations
Skeletal Manifestations of Metabolic Bone Disease Mishaela R. Rubin, MD February 21, 2008 The Three Ages of Women Gustav Klimt 1905 1 Lecture Outline Osteoporosis epidemiology diagnosis secondary causes
More informationWHO Absolute Fracture Risk Models (FRAX): Do Clinical Risk Factors Improve Fracture Prediction in Older Women Without Osteoporosis?
ORIGINAL ARTICLE JBMR WHO Absolute Fracture Risk Models (FRAX): Do Clinical Risk Factors Improve Fracture Prediction in Older Women Without Osteoporosis? Teresa A Hillier, 1 Jane A Cauley, 2 Joanne H Rizzo,
More informationOSTEOPOROSIS MANAGEMENT AND INVESTIGATION. David A. Hanley, MD, FRCPC
OSTEOPOROSIS MANAGEMENT AND INVESTIGATION David A. Hanley, MD, FRCPC There is a huge care gap in the management of osteoporosis in this country. As yet unpublished findings from the Canadian Multicentre
More informationCASE 1 WHY IS IT IMPORTANT TO TREAT? FACTS CONCERNS
4:30-5:15pm Ask the Expert: Osteoporosis SPEAKERS Silvina Levis, MD OSTEOPOROSIS - FACTS 1:3 older women and 1:5 older men will have a fragility fracture after age 50 After 3 years of treatment, depending
More informationOsteoporosis in Men. Until recently, the diagnosis of osteoporosis. A New Type of Patient. Al s case. How is the diagnosis made?
A New Type of Patient Rafat Faraawi, MD, FRCP(C), FACP Until recently, the diagnosis of osteoporosis in men was uncommon and, when present, it was typically described as a consequence of secondary causes.
More informationSubmission to the National Institute for Clinical Excellence on
Submission to the National Institute for Clinical Excellence on Strontium ranelate for the prevention of osteoporotic fractures in postmenopausal women with osteoporosis by The Society for Endocrinology
More informationThe Significance of Vertebral Fractures
Special Report The Significance of Vertebral Fractures Both the prevalence and the clinical significance of vertebral fractures has been greatly underestimated by physicians. Vertebral fractures are much
More informationCurrent Use of Unopposed Estrogen and Estrogen Plus Progestin and the Risk of Acute Myocardial Infarction Among Women With Diabetes
Current Use of Unopposed Estrogen and Estrogen Plus Progestin and the Risk of Acute Myocardial Infarction Among Women With Diabetes The Northern California Kaiser Permanente Diabetes Registry, 1995 1998
More informationAvailable online at ScienceDirect. Osteoporosis and Sarcopenia 1 (2015) 109e114. Original article
HOSTED BY Available online at www.sciencedirect.com ScienceDirect Osteoporosis and Sarcopenia 1 (2015) 109e114 Original article Localized femoral BMD T-scores according to the fracture site of hip and
More informationThe New England Journal of Medicine
The New England Journal of Medicine Copyright, 1997, by the Massachusetts Medical Society VOLUME 336 J UNE 19, 1997 NUMBER 25 POSTMENOPAUSAL HORMONE THERAPY AND MORTALITY FRANCINE GRODSTEIN, SC.D., MEIR
More informationInternational Journal of Health Sciences and Research ISSN:
International Journal of Health Sciences and Research www.ijhsr.org ISSN: 2249-9571 Original Research Article Osteoporosis- Do We Need to Think Beyond Bone Mineral Density? Dr Preeti Soni 1, Dr Shipra
More informationComparison of Bone Density of Distal Radius With Hip and Spine Using DXA
ORIGINAL ARTICLE Comparison of Bone Density of Distal Radius With Hip and Spine Using DXA Leila Amiri 1, Azita Kheiltash 2, Shafieh Movassaghi 1, Maryam Moghaddassi 1, and Leila Seddigh 2 1 Rheumatology
More informationAn audit of bone densitometry practice with reference to ISCD, IOF and NOF guidelines
Osteoporos Int (2006) 17: 1111 1115 DOI 10.1007/s00198-006-0101-6 SHORT COMMUNICATION An audit of bone densitometry practice with reference to ISCD, IOF and NOF guidelines R. Baddoura. H. Awada. J. Okais.
More informationDoes raloxifene (Evista) prevent fractures in postmenopausal women with osteoporosis?
FPIN's Clinical Inquiries Raloxifene for Prevention of Osteoporotic Fractures Clinical Inquiries provides answers to questions submitted by practicing family physicians to the Family Physicians Inquiries
More informationAPPROXIMATELY 1.5 MILLION
ORIGINAL CONTRIBUTION High-Trauma s and Low Bone Mineral Density in Older Women and Men Dawn C. Mackey, MSc Li-Yung Lui, MA, MS Peggy M. Cawthon, PhD Douglas C. Bauer, MD Michael C. Nevitt, PhD Jane A.
More informationTitle. Bow, CH; Tsang, SWY; Loong, CHN; Soong, CSS; Yeung, SC; Kung, AWC. Author(s)
Title Author(s) Bone mineral density enhances use of clinical risk factors in predicting ten-year risk of osteoporotic fractures in Chinese men: The Hong Kong Osteoporosis Study Bow, CH; Tsang, SWY; Loong,
More informationPostmenopausal osteoporosis is a systemic
OSTEOPOROSIS: HARD FACTS ABOUT BONES Steven T. Harris, MD, FACP* ABSTRACT As a consequence of the aging process, osteoporosis affects all men and women. Agerelated loss of bone mass leads to skeletal fragility
More informationCorrelation between Thyroid Function and Bone Mineral Density in Elderly People
IBBJ Spring 2016, Vol 2, No 2 Original Article Correlation between Thyroid Function and Bone Mineral Density in Elderly People Ali Mirzapour 1, Fatemeh Shahnavazi 2, Ahmad Karkhah 3, Seyed Reza Hosseini
More informationClinical risk factor assessment had better discriminative ability than bone mineral density in identifying subjects with vertebral fracture
Osteoporos Int (2011) 22:667 674 DOI 10.1007/s00198-010-1260-z ORIGINAL ARTICLE Clinical risk factor assessment had better discriminative ability than bone mineral density in identifying subjects with
More informationInterpreting DEXA Scan and. the New Fracture Risk. Assessment. Algorithm
Interpreting DEXA Scan and the New Fracture Risk Assessment Algorithm Prof. Samir Elbadawy *Osteoporosis affect 30%-40% of women in western countries and almost 15% of men after the age of 50 years. Osteoporosis
More informationAMERICAN COLLEGE OF RHEUMATOLOGY POSITION STATEMENT. Committee on Rheumatologic Care
AMERICAN COLLEGE OF RHEUMATOLOGY POSITION STATEMENT SUBJECT: PRESENTED BY: FOR DISTRIBUTION TO: Bone Mineral Density Measurement and the Role of Rheumatologists in the Management of Osteoporosis Committee
More informationIssues concerning the use of hormone replacement therapy and risk of fracture: a population-based, nested case-control study
British Journal of Clinical Pharmacology DOI:10.1111/j.1365-2125.2007.02904.x Issues concerning the use of hormone replacement therapy and risk of fracture: a population-based, nested case-control study
More informationOsteoporosis/Fracture Prevention
Osteoporosis/Fracture Prevention NATIONAL GUIDELINE SUMMARY This guideline was developed using an evidence-based methodology by the KP National Osteoporosis/Fracture Prevention Guideline Development Team
More informationOral Alendronate Vs. Three-Monthly Iv Ibandronate In The Treatment Of Postmenopausal Osteoporosis
Oral Alendronate Vs. Three-Monthly Iv Ibandronate In The Treatment Of Postmenopausal Osteoporosis Miriam Silverberg A. Study Purpose and Rationale More than 70% of fractures in people after the age of
More informationOsteoporosis Screening and Treatment in Type 2 Diabetes
Osteoporosis Screening and Treatment in Type 2 Diabetes Ann Schwartz, PhD! Dept. of Epidemiology and Biostatistics! University of California San Francisco! October 2011! Presenter Disclosure Information
More informationJuly 2012 CME (35 minutes) 7/12/2016
Financial Disclosures Epidemiology and Consequences of Fractures Advisory Board: Amgen Janssen Pharmaceuticals Inc. Ann V. Schwartz, PhD Department of Epidemiology and Biostatistics UCSF Outline Osteoporotic
More informationAssessment and Treatment of Osteoporosis Professor T.Masud
Assessment and Treatment of Osteoporosis Professor T.Masud Nottingham University Hospitals NHS Trust University of Nottingham University of Derby University of Southern Denmark What is Osteoporosis? Osteoporosis
More informationSERMS, Hormone Therapy and Calcitonin
SERMS, Hormone Therapy and Calcitonin Tiffany Kim, MD Clinical Fellow VA Advanced Women s Health UCSF Endocrinology and Metabolism I have nothing to disclose Thanks to Clifford Rosen and Steven Cummings
More informationInternational Journal of Advanced Research in Biological Sciences ISSN : Research Article
Int. J. Adv. Res. Biol.Sci. 1(7): (2014): 167 172 International Journal of Advanced Research in Biological Sciences ISSN : 2348-8069 www.ijarbs.com Research Article Beneficial effect of Strontium Ranelate
More informationConcordance of a Self Assessment Tool and Measurement of Bone Mineral Density in Identifying the Risk of Osteoporosis in Elderly Taiwanese Women
TZU CHI MED J September 2008 Vol 20 No 3 available at http://ajws.elsevier.com/tcmj Tzu Chi Medical Journal Original Article Concordance of a Self Assessment Tool and Measurement of Bone Mineral Density
More informationFragile Bones and how to recognise them. Rod Hughes Consultant physician and rheumatologist St Peter s hospital Chertsey
Fragile Bones and how to recognise them Rod Hughes Consultant physician and rheumatologist St Peter s hospital Chertsey Osteoporosis Osteoporosis is a skeletal disorder characterised by compromised bone
More informationRisk Factors for Increased Bone Loss in an Elderly Population
American Journal of Epidemiology Copyright 1998 by The Johns Hopkins University School of Hygiene and Public Health All rights reserved Vol. 147, No. 9 Printed in U.S.A. Risk Factors for Increased Bone
More informationNEW DEVELOPMENTS IN OSTEOPOROSIS: SCREENING, PREVENTION AND TREATMENT
NEW DEVELOPMENTS IN OSTEOPOROSIS: SCREENING, PREVENTION AND TREATMENT Judith Walsh, MD, MPH Departments of Medicine and Epidemiology and Biostatistics UCSF OSTEOPOROSIS: OVERVIEW Definitions Risk factors
More informationNIH Public Access Author Manuscript Osteoporos Int. Author manuscript; available in PMC 2011 January 8.
NIH Public Access Author Manuscript Published in final edited form as: Osteoporos Int. 2011 January ; 22(1): 345 349. doi:10.1007/s00198-010-1179-4. Does Dietary Protein Reduce Hip Fracture Risk in Elders?
More informationUse of DXA / Bone Density in the Care of Your Patients. Brenda Lee Holbert, M.D. Associate Professor Senior Staff Radiologist
Use of DXA / Bone Density in the Care of Your Patients Brenda Lee Holbert, M.D. Associate Professor Senior Staff Radiologist Important Websites Resources for Clinicians and Patients www.nof.org www.iofbonehealth.org
More informationDECADES OF PUBLISHED STUDIES have confirmed the
JOURNAL OF BONE AND MINERAL RESEARCH Volume 15, Number 2, 2000 2000 American Society for Bone and Mineral Research Perspective Bone Matters: Are Density Increases Necessary to Reduce Fracture Risk? KENNETH
More informationAn audit of osteoporotic patients in an Australian general practice
professional Darren Parker An audit of osteoporotic patients in an Australian general practice Background Osteoporosis is a major contributor to morbidity and mortality in Australia, and is predicted to
More informationOsteoporosis. Overview
v2 Osteoporosis Overview Osteoporosis is defined as compromised bone strength that increases risk of fracture (NIH Consensus Conference, 2000). Bone strength is characterized by bone mineral density (BMD)
More informationDiagnosis of Vertebral Fractures by Vertebral Fracture Assessment
Journal of Clinical Densitometry, vol. 9, no. 1, 66 71, 2006 Ó Copyright 2006 by The International Society for Clinical Densitometry 1094-6950/06/9:66 71/$32.00 DOI: 10.1016/j.jocd.2005.11.002 Original
More informationLong-term Osteoporosis Therapy What To Do After 5 Years?
Long-term Osteoporosis Therapy What To Do After 5 Years? Developing a Long-term Management Plan North American Menopause Society Philadelphia, PA October 11, 2017 Michael R. McClung, MD, FACP Institute
More informationCLINICIAN INTERVIEW CARDIOVASCULAR DISEASE IN POSTMENOPAUSAL WOMEN
CARDIOVASCULAR DISEASE IN POSTMENOPAUSAL WOMEN Nanette K. Wenger, MD, is a recognized authority on women and coronary heart disease. She chaired the US National Heart, Lung, and Blood Institute conference
More informationjournal of medicine The new england One Year of Alendronate after One Year of Parathyroid Hormone (1 84) for Osteoporosis abstract
The new england journal of medicine established in 112 august 11, 25 vol. 353 no. 6 One Year of Alendronate after One Year of Parathyroid Hormone (1 ) for Osteoporosis Dennis M. Black, Ph.D., John P. Bilezikian,
More informationOsteoporosis is a disease that is
Pharmacologic Prevention of Osteoporotic Fractures THOMAS M. ZIZIC, M.D., Johns Hopkins University School of Medicine, Baltimore, Maryland Osteoporosis is characterized by low bone mineral density and
More informationForteo (teriparatide) Prior Authorization Program Summary
Forteo (teriparatide) Prior Authorization Program Summary FDA APPROVED INDICATIONS DOSAGE 1 FDA Indication 1 : Forteo (teriparatide) is indicated for: the treatment of postmenopausal women with osteoporosis
More informationW hile the headline-grabbing Women s
OBG MANAGEMENT BY ROBERT L. BARBIERI, MD New options in osteoporosis therapy: Combination and sequential treatment Perhaps the biggest medical question to emerge from the WHI study is how to best treat
More informationPharmacy Management Drug Policy
Clinical criteria used to make utilization review decisions are based on credible scientific evidence published in peer reviewed medical literature generally recognized by the medical community. Guidelines
More informationHormone replacement therapy in young women with karyotypically normal spontaneous premature ovarian failure [protocol]
Página 1 de 7 Hormone replacement therapy in young women with karyotypically normal spontaneous premature ovarian failure [protocol] Kalantaridou SN, Calis KA, Nelson LM. This protocol should be cited
More informationPharmacy Management Drug Policy
SUBJECT: - Forteo (teriparatide), Prolia (denosumab), Tymlos (abaloparatide) POLICY NUMBER: Pharmacy-35 EFFECTIVE DATE: 9/07 LAST REVIEW DATE: 9/29/2017 If the member s subscriber contract excludes coverage
More informationOsteoporosis is estimated to develop in 1 out of 4 women over the age of 50. Influence of bone densitometry results on the treatment of osteoporosis
Influence of bone densitometry results on the treatment of osteoporosis Nicole S. Fitt, * Susan L. Mitchell, * Ann Cranney, Karen Gulenchyn, Max Huang, * Peter Tugwell Abstract Background: Measurement
More informationISPUB.COM. Screening for Osteoporosis in Postmenopausal Women: Recommendations and Rationale: U.S. Preventive Services Task Force
ISPUB.COM The Internet Journal of Family Practice Volume 2 Number 2 Screening for Osteoporosis in Postmenopausal Women: Recommendations and Rationale: U.S. Preventive Services Task Force United States
More informationOsteoporosis - recent advances in diagnosis and treatment
Title Osteoporosis - recent advances in diagnosis and treatment Author(s) Kung, AWC Citation The 4th Medical Research Conference (MRC 1999), Hong Kong, China, 30-31 January 1999. In Hong Kong Practitioner,
More informationUse of Statins and Fracture
ORIGINAL INVESTIGATION Use of Statins and Fracture Results of 4 Prospective Studies and Cumulative Meta-analysis of Observational Studies and Controlled Trials Douglas C. Bauer, MD; Greg R. Mundy, MD;
More information1
www.osteoporosis.ca 1 2 Overview of the Presentation Osteoporosis: An Overview Bone Basics Diagnosis of Osteoporosis Drug Therapies Risk Reduction Living with Osteoporosis 3 What is Osteoporosis? Osteoporosis:
More informationDifferentiating Pharmacological Therapies for Osteoporosis
Differentiating Pharmacological Therapies for Osteoporosis Socrates E Papapoulos Department of Endocrinology & Metabolic Diseases Leiden University Medical Center The Netherlands Competing interests: consulting/speaking
More informationThe preferred treatment for osteoporosis
Alternate Options to Hormone Replacement Therapy for Osteoporosis James R. Shoemaker, DO Andrea B. Klemes, DO This presentation, developed from a symposium lecture at the 40th Annual Convention of the
More informationEffective Health Care
Number 12 Effective Health Care Comparative Effectiveness of Treatments To Prevent Fractures in Men and Women With Low Bone Density or Osteoporosis Executive Summary Background Osteoporosis is a systemic
More informationPROSPECTIVE STUDIES HAVE
ORIGINAL CONTRIBUTION Serum Estradiol Level and Risk of Breast Cancer During Treatment With Steven R. Cummings, MD Tu Duong, MA Emily Kenyon, PhD Jane A. Cauley, DrPH Malcolm Whitehead, MB,BS, FRCOG Kathryn
More informationRisk Factors for Postmenopausal Fractures What We Have Learned from The OSTPRE - study
Risk Factors for Postmenopausal Fractures What We Have Learned from The OSTPRE - study Heikki Kröger Kuopio Musculoskeletal Research Unit, University of Eastern Finland (UEF) Dept. of Orthopaedics, Traumatology
More informationBone Mineral Density and Its Associated Factors in Naresuan University Staff
Naresuan University Journal 2005; 13(3): 13-18 13 Bone Mineral Density and Its Associated Factors in Naresuan University Staff Supawitoo Sookpeng *, Patsuree Cheebsumon, Malinee Dhanarun, Thanyavee Pengpan
More informationBMD: A Continuum of Risk WHO Bone Density Criteria
Pathogenesis of Osteoporosis Osteoporosis Diagnosis: BMD, FRAX and Assessment of Secondary Osteoporosis AGING MENOPAUSE OTHER RISK FACTORS RESORPTION > FORMATION Bone Loss LOW PEAK BONE MASS Steven T Harris
More informationOsteoporosis: An Overview. Carolyn J. Crandall, MD, MS
Osteoporosis: An Overview Carolyn J. Crandall, MD, MS Osteoporosis: An Overview Carolyn J. Crandall, MD, MS Professor of Medicine David Geffen School of Medicine at UCLA Objectives Review osteoporosis
More informationPrevalence of Osteoporosis p. 262 Consequences of Osteoporosis p. 263 Risk Factors for Osteoporosis p. 264 Attainment of Peak Bone Density p.
Dedication Preface Acknowledgments Continuing Education An Introduction to Conventions in Densitometry p. 1 Densitometry as a Quantitative Measurement Technique p. 2 Accuracy and Precision p. 2 The Skeleton
More informationO. Bruyère M. Fossi B. Zegels L. Leonori M. Hiligsmann A. Neuprez J.-Y. Reginster
DOI 10.1007/s00296-012-2460-y ORIGINAL ARTICLE Comparison of the proportion of patients potentially treated with an anti-osteoporotic drug using the current criteria of the Belgian national social security
More informationOutline Vertebroplasty and Kyphoplasty: Who, What, and When
Outline Vertebroplasty and Kyphoplasty: Who, What, and When Douglas C. Bauer, MD University of California San Francisco, USA Vertebral fracture epidemiology, consequences and diagnosis Kyphoplasty and
More informationBone Mass Measurement BONE MASS MEASUREMENT HS-042. Policy Number: HS-042. Original Effective Date: 8/25/2008
Easy Choice Health Plan, Inc. Harmony Health Plan of Illinois, Inc. Missouri Care, Inc. Ohana Health Plan, a plan offered by WellCare Health Insurance of Arizona, Inc. WellCare Health Insurance of Illinois,
More informationOSTEOPOROSIS IN MEN. Nelson B. Watts, MD OSTEOPOROSIS AND BONE HEALTH SERVICES CINCINNATI, OHIO
OSTEOPOROSIS IN MEN Nelson B. Watts, MD OSTEOPOROSIS AND BONE HEALTH SERVICES CINCINNATI, OHIO DISCLOSURES Speakers Bureau: Amgen, Radius Consultant: Abbvie, Amgen, Janssen, Radius, Sanofi Watts NB et
More informationORIGINAL INVESTIGATION. Bone Mineral Density Thresholds for Pharmacological Intervention to Prevent Fractures
ORIGINAL INVESTIGATION Bone Mineral Density Thresholds for Pharmacological Intervention to Prevent Fractures Ethel S. Siris, MD; Ya-Ting Chen, PhD; Thomas A. Abbott, PhD; Elizabeth Barrett-Connor, MD;
More informationUsing the FRAX Tool. Osteoporosis Definition
How long will your bones remain standing? Using the FRAX Tool Gary Salzman M.D. Director Banner Good Samaritan/ Hayden VAMC Internal Medicine Geriatric Fellowship Program Phoenix, Arizona Using the FRAX
More informationAnalysis of Clinical Features of Hip Fracture Patients with or without Prior Osteoporotic Spinal Compression Fractures
J Bone Metab 2013;20:11-15 http://dx.doi.org/10.11005/jbm.2013.20.1.11 pissn 2287-6375 eissn 2287-7029 Original Article Analysis of Clinical Features of Hip Fracture Patients with or without Prior Osteoporotic
More information